Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW. De Vleeschouwer S, et al. Among authors: kaempgen e. Clin Cancer Res. 2008 May 15;14(10):3098-104. doi: 10.1158/1078-0432.CCR-07-4875. Clin Cancer Res. 2008. PMID: 18483377 Free article. Clinical Trial.
Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report.
De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff JE, Plets C, Sciot R, Van Gool SW. De Vleeschouwer S, et al. Among authors: kaempgen e. J Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7. doi: 10.3171/ped.2004.100.5.0492. J Neurosurg. 2004. PMID: 15287461
Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E. Lennerz V, et al. Among authors: kaempgen e. Cancer Immunol Immunother. 2014 Apr;63(4):381-94. doi: 10.1007/s00262-013-1516-5. Epub 2014 Feb 2. Cancer Immunol Immunother. 2014. PMID: 24487961 Free PMC article. Clinical Trial.
Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers.
Gross S, Lennerz V, Gallerani E, Mach N, Böhm S, Hess D, von Boehmer L, Knuth A, Ochsenbein A, Gnad-Vogt U, Forssmann U, Woelfel T, Kaempgen E. Gross S, et al. Among authors: kaempgen e. Cancer Immunol Res. 2016 Jan;4(1):18-25. doi: 10.1158/2326-6066.CIR-15-0105. Epub 2015 Nov 12. Cancer Immunol Res. 2016. PMID: 26563311 Clinical Trial.
Late-type allergy to Ultravist (iopromid).
Otto K, Kaempgen E, Dummer W, Broecker EB, Becker JC. Otto K, et al. Among authors: kaempgen e. Allergy. 2003 Mar;58(3):261-2. doi: 10.1034/j.1398-9995.2003.00062_3.x. Allergy. 2003. PMID: 12653805 No abstract available.
Assessment of sorafenib induced changes in tumor perfusion of uveal melanoma metastases with dynamic contrast-enhanced ultrasound (DCE-US).
Wildner D, Heinzerling L, Scheulen ME, Kaempgen E, Schuler G, Strobel D, Janka R, Neurath MF, Sturm J, Knieling F. Wildner D, et al. Among authors: kaempgen e. J Cancer Res Clin Oncol. 2022 Apr;148(4):955-965. doi: 10.1007/s00432-021-03666-8. Epub 2021 May 28. J Cancer Res Clin Oncol. 2022. PMID: 34050396 Free PMC article.
18 results